Vaccine Scheduler
Bulgaria and Greece: Comparison of recommended vaccinations
| Bulgaria | Greece | |
|---|---|---|
| General recommendation | ||
| Recommendation for specific groups only | ||
| Catch-up (e.g. if previous doses missed) | ||
| Vaccination not funded by the National Health system | ||
| Mandatory vaccination | ||
| Birth | Months | Years | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 11 | 12 | 13 | 15 | 16 | 18 | 19 | 23 | 2-3 | 4 | 5 | 6 | 7 | 9 | 10 | 11 | 12 | 13 | 17 | 18 | ||||
| Coronavirus disease (COVID-19)1, 2 | COVID-198 | |||||||||||||||||||||||||||||
| COVID-192 | ||||||||||||||||||||||||||||||
| tuberculosis | BCG9 | BCG10 | BCG11 | BCG11 | BCG11 | |||||||||||||||||||||||||
| BCG12 | ||||||||||||||||||||||||||||||
| rotavirus infection3 | ||||||||||||||||||||||||||||||
| ROTA | ROTA | ROTA | ||||||||||||||||||||||||||||
| diphtheria | D | D | D | D13 | D | d | d | |||||||||||||||||||||||
| D | D | D | D | D | D | D | d | d | d | |||||||||||||||||||||
| tetanus | TT | TT | TT | TT13 | TT | TT | TT | |||||||||||||||||||||||
| TT | TT | TT | TT | TT | TT | TT | TT | TT | TT | |||||||||||||||||||||
| pertussis | acP | acP | acP | acP13 | acP | acp | ||||||||||||||||||||||||
| acP | acP | acP | acP | acp | acp | acP | acp | acp | acp | |||||||||||||||||||||
| poliomyelitis | IPV | IPV | IPV | IPV13 | IPV | |||||||||||||||||||||||||
| IPV | IPV | IPV | IPV | IPV | IPV | |||||||||||||||||||||||||
| Haemophilus influenzae type b infection | Hib | Hib | Hib | Hib13 | ||||||||||||||||||||||||||
| Hib | Hib | Hib | Hib | Hib | Hib | Hib | ||||||||||||||||||||||||
| hepatitis B | HepB14 | HepB15 | HepB16 | HepB16 | HepB16 | HepB15 | ||||||||||||||||||||||||
| HepB17 | HepB | HepB | HepB | HepB | ||||||||||||||||||||||||||
| pneumococcal disease4 | PCV | PCV | PCV18 | |||||||||||||||||||||||||||
| PCV13 or PCV 15 | PCV13 or PCV 15 | PCV13 or PCV 15 | PCV13 or PCV 15 | PCV13 or PCV 15 | PCV+PPSV2319 | |||||||||||||||||||||||||
| meningococcal disease5 | ||||||||||||||||||||||||||||||
| MCV4/MenB | MenC | MenC | MCV4 | MCV4 | ||||||||||||||||||||||||||
| measles6 | MEAS | MEAS | ||||||||||||||||||||||||||||
| MEAS | MEAS | MEAS | MEAS | |||||||||||||||||||||||||||
| mumps | MUMPS | MUMPS | ||||||||||||||||||||||||||||
| MUMPS | MUMPS | MUMPS | MUMPS | |||||||||||||||||||||||||||
| rubella | RUBE | RUBE | ||||||||||||||||||||||||||||
| RUBE | RUBE | RUBE | RUBE | |||||||||||||||||||||||||||
| varicella | ||||||||||||||||||||||||||||||
| VAR | VAR | VAR | VAR | |||||||||||||||||||||||||||
| human papillomavirus infection | HPV (F)20 | |||||||||||||||||||||||||||||
| HPV (F/M)21 | ||||||||||||||||||||||||||||||
| influenza | ||||||||||||||||||||||||||||||
| IIV3 | ||||||||||||||||||||||||||||||
| herpes zoster7 | ||||||||||||||||||||||||||||||
| ZOS22 | ||||||||||||||||||||||||||||||
| hepatitis A | ||||||||||||||||||||||||||||||
| HepA | HepA | |||||||||||||||||||||||||||||
Footnotes:
- https://www.mh.government.bg/bg/novini/aktualno/nacionalen-plan-za-vaksinirane-sreshu-covid-19-v-r/?fbclid=IwAR1xtwkQGiTub7t4F7EheRqEm2gz7QUUYvBOmhpGbFMZeVp0GD3AdSpzTlc
- https://emvolio.gov.gr/
- 2 doses of RV1 (month 2 and 4) OR 3 doses of RV5 (month 2, 4 and 6)
- PPSV23 recommended from 2 years of age in at-risk groups
- MenACWY is recommended to all adolescents aged 11-12 years. It is also recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 6 months of age are recommended 3 doses at ages 2, 4 and 12 months (MenACWY-TT vaccine); Infants starting vaccination between 7 and 24 months: 2 doses, 2nd dose to is administered at least 12 weeks after the first dose (MenACWY-TT vaccine); Children starting vaccination after 2 years of age: 2 doses with 8 weeks interval (MenACWY-CRM or MenACWY-TT vaccine); In children who remain at high risk, a booster dose is recommended 3-5 years after completion of their primary course. The MenB vaccine is recommended to infants and children (aged 2 months to 18 years) in increased risk categories. Infants starting vaccination at 2 to 5 months of age are recommended 4 doses at ages 2, 4, 6 and 12–15 months (MenB-4C); Infants and toddlers starting vaccination at 6 to 23 months of age: 2 doses with minimum 8 weeks interval and a booster dose at age 12–23 months (MenB-4C); Children starting vaccination at 2 to 10 years of age: 2 doses with minimum 8 weeks interval (MenB-4C); Children starting vaccination from the age of 11 years: 2 doses with minimum interval of 1 month (MenB-4C); Individuals aged 10 years and above can be vaccinated with MenB-fHbp with a 3-dose regimen at 0, 1–2, 6 months. More details available at: http://www.infovac.gr/wp-content/uploads/2019/06/%CE%95%CE%98%CE%9D%CE%99%CE%9A%CE%9F-%CE%A0%CE%A1%CE%9F%CE%93%CE%A1%CE%91%CE%9C%CE%9C%CE%91-%CE%95%CE%9C%CE%92%CE%9F%CE%9B%CE%99%CE%91%CE%A3%CE%9C%CE%A9%CE%9D-%CE%A0%CE%91%CE%94%CE%99%CE%A9%CE%9D-%CE%95%CE%A6%CE%97%CE%92%CE%A9%CE%9D-2019.pdf
- 21 Sept. 2017: temporary recommendation for measles vaccination in Greece. First Dose at 12 months of age, Second dose 3 months later or 4 weeks after Dose 1 in specific groups
- for detailled information refer to https://www.moh.gov.gr/articles/health/dieythynsh-dhmosias-ygieinhs/emboliasmoi/alles-systaseis-ths-ethnikhs-epitrophs-emboliasmwn/11437-skeptiko-emboliasmoy-gia-ton-erphta-zwsthra-aprilios-2023
- https://www.mh.government.bg/bg/covid-19/informaciya-otnosno-noviya-koronavirus-2019-ncov/
- Administration after 48 hours from birth.
- Only after negative Montoux test
- Booster dose after negative Montoux test
- Vaccination is also recommended for infants and children up to the age of 5 years who belong to an increased risk groups and who have not been previously vaccinated
- Not earlier than 12 months after the 3rd dose
- Administration within 24 hours after birth.
- When using a monovalent vacine, doses are administered at 1 and 6 months
- When using a combination vaccine (e.g. hexavalent vaccine), doses are administered at 2, 3 and 4 months
- Babies born to a mother infected with hepatitis B (or with unknown status) will be offered a first vaccine dose at birth simultaneously with HB immunoglobulin. More details on follow-up schedule are available at: http://www.infovac.gr/wp-content/uploads/2019/06/%CE%95%CE%98%CE%9D%CE%99%CE%9A%CE%9F-%CE%A0%CE%A1%CE%9F%CE%93%CE%A1%CE%91%CE%9C%CE%9C%CE%91-%CE%95%CE%9C%CE%92%CE%9F%CE%9B%CE%99%CE%91%CE%A3%CE%9C%CE%A9%CE%9D-%CE%A0%CE%91%CE%94%CE%99%CE%A9%CE%9D-%CE%95%CE%A6%CE%97%CE%92%CE%A9%CE%9D-2019.pdf
- Not earlier than 6 months after the previous dose
- PPSV is recommended in addition to PCV13 or PCV15 at least 2 months after the last dose of PCV13 in subjects > 2 years with an increased risk of disease from pneumococcal infections. A booster dose of PPSV23 is recommended 5 years after the first dose
- Girls-only vaccination offered. HPV vaccination is free of charge but voluntary and not included in the National mandatory Immunisation schedule but as part of the National program for primary prophylaxis of cervical cancer 2021-2024. 2 and 4 valent vaccine administered.
- Catch-up vaccination up to 18 years for those who missed out on vaccination (HPV vaccine is fully reimbursed in boys and girls aged 15-18 until 31.12.2023). 2 doses scheme up to 15 years with 6 months interval between doses, thereafter 3 doses. for specific at-risk groups vaccination can be extended up to 26 years.
- 2 doses (RZV vaccine) in immunocompromised with 2 or more episodes of herpes-zoster